LIVIVO - Search results -

Search results

Result 1 - 10 of total 53

Search options

Article ; Online: Association Between Baclofen and Respiratory Depression in Patients With Chronic Kidney Disease.

Mitsuboshi, Satoru

2021 Volume 61, Issue 6, Page(s) 836–837

MeSH term(s)	Age Factors ; Aged ; Baclofen/adverse effects ; Baclofen/pharmacokinetics ; Body Weight ; Female ; Humans ; Male ; Middle Aged ; Propiophenones/therapeutic use ; Renal Insufficiency, Chronic/epidemiology ; Respiratory Insufficiency/chemically induced ; Sex Factors
Chemical Substances	Propiophenones ; eperisone (2M2P0551D3) ; Baclofen (H789N3FKE8)
Language	English
Publishing date	2021-03-27
Publishing country	England
Document type	Letter ; Observational Study
ZDB-ID	188980-1
ISSN	1552-4604 ; 0091-2700 ; 0021-9754
ISSN (online)	1552-4604
ISSN	0091-2700 ; 0021-9754
DOI	10.1002/jcph.1843
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.176: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Risk of haematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: Analysis of the Japanese Adverse Drug Event Report database.

Mitsuboshi, Satoru

British journal of clinical pharmacology

2020 Volume 87, Issue 5, Page(s) 2286–2289

Abstract: Although methotrexate (MTX) for rheumatoid arthritis (RA) sometimes causes severe haematological toxicities in users with chronic kidney disease (CKD), data are limited regarding the risk of these events and the preventive effect of folic acid. This ... ...

Abstract	Although methotrexate (MTX) for rheumatoid arthritis (RA) sometimes causes severe haematological toxicities in users with chronic kidney disease (CKD), data are limited regarding the risk of these events and the preventive effect of folic acid. This study evaluated the risk of haematological toxicities and the efficacy of folic acid in MTX users with CKD using the Japanese Adverse Drug Event Report. In total, 5,648 oral MTX users with RA were identified, including 630 with haematological toxicities. MTX users with CKD had significantly increased risk of haematological toxicities compared with those without CKD when folic acid was not used (OR 3.72; 95% CI 2.87-4.81; P < 0.01). Multivariate logistic analysis showed that the risk of haematological toxicities was significantly decreased by only folic acid (OR 0.16; 95% CI 0.04-0.62; P < 0.01). This result provides useful information for preventing severe haematological toxicities in MTX users with CKD and RA.
Language	English
Publishing date	2020-12-16
Publishing country	England
Document type	Journal Article
ZDB-ID	188974-6
ISSN	1365-2125 ; 0306-5251 ; 0264-3774
ISSN (online)	1365-2125
ISSN	0306-5251 ; 0264-3774
DOI	10.1111/bcp.14641
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1118: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Association between use of febuxostat and muscle injury: A disproportionality analysis and meta-analysis of randomized controlled trials.

Mitsuboshi, Satoru / Kotake, Kazumasa

British journal of clinical pharmacology

2023 Volume 89, Issue 3, Page(s) 956–966

Abstract: Aims: Several reports have suggested an association between febuxostat and muscle injury. The purpose of this study was to determine whether febuxostat increases the risk of muscle injury. This study included an analysis of the US Food and Drug ... ...

Abstract	Aims: Several reports have suggested an association between febuxostat and muscle injury. The purpose of this study was to determine whether febuxostat increases the risk of muscle injury. This study included an analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database and a systematic review/meta-analysis of randomized controlled trials. Methods: First, evaluation of the FAERS data included a disproportionality analysis that compared patients with and without rhabdomyolysis according to whether they were receiving febuxostat or allopurinol. Second, a systematic review/meta-analysis was performed to assess the risk of rhabdomyolysis and muscle injury in patients who used febuxostat or allopurinol. Results: Analysis of the FAERS data revealed disproportionality for increasing rhabdomyolysis in patients who received febuxostat (reporting odds ratio 4.49, 95% confidence interval [CI] 3.72-5.38, P < .01) and allopurinol (reporting odds ratio 2.49, 95% CI 2.25-2.75, P < .01). Nineteen studies were eligible for inclusion in the systematic review/meta-analysis. Rhabdomyolysis was reported in only 1 study. The risk of any type of muscle damage was not significantly increased with febuxostat compared with placebo (risk ratio 0.92, 95% CI 0.73-1.17, P = .52, I Conclusion: Febuxostat does not seem to affect the risk of muscle injury. However, the findings of this meta-analysis indicate a need for further high-quality observational studies with long-term follow-up.
MeSH term(s)	Humans ; Allopurinol/adverse effects ; Febuxostat/adverse effects ; Gout/drug therapy ; Gout Suppressants/adverse effects ; Muscles ; Muscular Diseases/chemically induced ; Randomized Controlled Trials as Topic ; Rhabdomyolysis/chemically induced ; Rhabdomyolysis/epidemiology
Chemical Substances	Allopurinol (63CZ7GJN5I) ; Febuxostat (101V0R1N2E) ; Gout Suppressants
Language	English
Publishing date	2023-01-11
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Systematic Review ; Research Support, Non-U.S. Gov't
ZDB-ID	188974-6
ISSN	1365-2125 ; 0306-5251 ; 0264-3774
ISSN (online)	1365-2125
ISSN	0306-5251 ; 0264-3774
DOI	10.1111/bcp.15655
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1118: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reply to: Comments on "Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics".

Mitsuboshi, Satoru / Hamano, Hirofumi / Zamami, Yoshito

International journal of cancer

2023 Volume 154, Issue 3, Page(s) 586–587

MeSH term(s)	Humans ; Sodium Chloride Symporter Inhibitors ; Immune Checkpoint Inhibitors/adverse effects ; Myocarditis/chemically induced
Chemical Substances	Sodium Chloride Symporter Inhibitors ; Immune Checkpoint Inhibitors
Language	English
Publishing date	2023-10-18
Publishing country	United States
Document type	Letter
ZDB-ID	218257-9
ISSN	1097-0215 ; 0020-7136
ISSN (online)	1097-0215
ISSN	0020-7136
DOI	10.1002/ijc.34767
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 478: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 576: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Individual dipeptidyl peptidase-4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta-analysis.

Mitsuboshi, Satoru / Morizumi, Makoto / Kotake, Kazumasa / Kaseda, Ryohei / Narita, Ichiei

Basic & clinical pharmacology & toxicology

2024

Abstract: This network meta-analysis of randomized controlled trials aimed to determine whether any individual dipeptidyl peptidase-4 (DPP-4) inhibitors increase the risk of acute kidney injury (AKI). The Medical Literature Analysis and Retrieval System Online via ...

Abstract	This network meta-analysis of randomized controlled trials aimed to determine whether any individual dipeptidyl peptidase-4 (DPP-4) inhibitors increase the risk of acute kidney injury (AKI). The Medical Literature Analysis and Retrieval System Online via PubMed, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were systematically searched to identify relevant studies. The primary outcome was AKI. A frequentist network meta-analysis was performed using a random-effects model to account for heterogeneity. Twenty-nine studies involving 56 117 participants were included. There were 918 cases of AKI (1.63%). The risk of bias was generally considered to be low. The only DPP-4 inhibitor that significantly increased the frequency of AKI when compared with placebo was sitagliptin (risk ratio 1.65, 95% confidence interval 1.22-2.23). However, because one study showed significant outliers in the funnel plot, in a highly heterogeneous population composed solely of patients undergoing surgery for coronary artery bypass graft, we conducted a post-hoc sensitivity analysis to exclude this study. The results showed no statistically significant difference in the risk of AKI between sitagliptin and placebo. Individual DPP-4 inhibitors do not appear to increase the risk of AKI. However, sitagliptin may be associated with AKI in patients with underlying severe cardiovascular disease.
Language	English
Publishing date	2024-05-02
Publishing country	England
Document type	Journal Article
ZDB-ID	2134679-3
ISSN	1742-7843 ; 1742-7835
ISSN (online)	1742-7843
ISSN	1742-7835
DOI	10.1111/bcpt.14014
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uf I Zs.144: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Risks of serious adverse events and kidney injury in patients treated with ibandronate: A systematic review and meta-analysis.

Mitsuboshi, Satoru / Kotake, Kazumasa

Pharmacotherapy

2022 Volume 42, Issue 8, Page(s) 677–686

Abstract: Background: Several reports suggest that adverse events caused by ibandronate are less serious than those associated with the other bisphosphonates. The purpose of this systematic review and meta-analysis was to determine whether ibandronate has low ... ...

Abstract	Background: Several reports suggest that adverse events caused by ibandronate are less serious than those associated with the other bisphosphonates. The purpose of this systematic review and meta-analysis was to determine whether ibandronate has low rates of serious adverse events and kidney injury. Methods: Randomized controlled trials were selected, and the study populations consisted of adult patients with osteoporosis. The primary outcome was all serious adverse events and the secondary outcome was kidney injury. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the quality of evidence. Results: Nineteen studies were eligible for inclusion. No significant difference in the rate of serious adverse events or that of kidney injury was found between ibandronate and placebo or between ibandronate and other bisphosphonates. However, a sensitivity analysis, which excluded studies at "high risk" of detection bias, found that the risk of serious adverse events was significantly lower for ibandronate than for the other bisphosphonates (risk ratio 0.79, 95% confidence interval 0.66-0.94, p < 0.01). This finding was assessed as high-quality evidence when the GRADE criteria were applied. Only five studies (26%) reported kidney injury as an adverse event. Conclusions: Limited evidence was found to suggest that ibandronate may carry a lower risk of serious adverse events compared with other bisphosphonates. Further high-quality randomized controlled trials are needed to compare the risk of kidney injury associated with the various bisphosphonates.
MeSH term(s)	Adult ; Bone Density Conservation Agents ; Diphosphonates ; Humans ; Ibandronic Acid ; Kidney ; Osteoporosis
Chemical Substances	Bone Density Conservation Agents ; Diphosphonates ; Ibandronic Acid (UMD7G2653W)
Language	English
Publishing date	2022-06-28
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Review ; Systematic Review
ZDB-ID	603158-4
ISSN	1875-9114 ; 0277-0008
ISSN (online)	1875-9114
ISSN	0277-0008
DOI	10.1002/phar.2713
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1738: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 585: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparison of different sustained-release opioids and acute respiratory conditions in patients with cancer and chronic kidney disease.

Mitsuboshi, Satoru / Imai, Shungo / Kizaki, Hayato / Hori, Satoko

Pharmacotherapy

2023 Volume 44, Issue 2, Page(s) 122–130

Abstract: Study objective: Few data are available on the association between the use of oxycodone in patients with chronic kidney disease (CKD) and acute respiratory conditions. The aim of this study was to investigate whether oxycodone is associated with an ... ...

Abstract	Study objective: Few data are available on the association between the use of oxycodone in patients with chronic kidney disease (CKD) and acute respiratory conditions. The aim of this study was to investigate whether oxycodone is associated with an increased risk of acute respiratory conditions in patients with cancer and CKD compared with other opioids. Design and setting: The data were obtained from a claims database in Japan. Patients with cancer and CKD who had received sustained-release opioids, including oral oxycodone, oral morphine, or transdermal fentanyl, between April 2014 and May 2021 were selected. The primary outcome was defined as an acute respiratory condition. Data for age and sex, morphine equivalent daily dose, concomitant use of specified medications, comorbidities defined based on the modified Charlson comorbidity index, substance use disorder, and lung cancer or metastatic lung cancer were investigated as covariates. Distribution of acute respiratory conditions was compared among the three sustained-release opioid groups using the log-rank test. Estimates of the incidence of acute respiratory conditions were compared among the groups using a Cox proportional hazards model with time-varying variables. Main results: A significant difference in the distribution of acute respiratory conditions was found among the three groups (p < 0.01). Cox regression analysis showed a significantly higher risk of acute respiratory conditions with morphine (hazard ratio [HR]: 3.04, 95% confidence interval [CI]: 1.07-8.65, p = 0.04) compared with oxycodone but no significant difference in risk with oxycodone (HR 0.67, 95% CI: 0.32-1.38, p = 0.27) compared with fentanyl. Conclusions: The findings suggest that the risk of acute respiratory conditions may be lower in patients with CKD who use oxycodone for cancer pain than in those who use morphine. Additionally, no difference in the risk of acute respiratory conditions was found between oxycodone and fentanyl use.
MeSH term(s)	Humans ; Analgesics, Opioid/adverse effects ; Oxycodone/adverse effects ; Pain/drug therapy ; Delayed-Action Preparations/therapeutic use ; Fentanyl/adverse effects ; Morphine/adverse effects ; Renal Insufficiency, Chronic/complications ; Neoplasms/chemically induced ; Lung Neoplasms/epidemiology
Chemical Substances	Analgesics, Opioid ; Oxycodone (CD35PMG570) ; Delayed-Action Preparations ; Fentanyl (UF599785JZ) ; Morphine (76I7G6D29C)
Language	English
Publishing date	2023-11-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	603158-4
ISSN	1875-9114 ; 0277-0008
ISSN (online)	1875-9114
ISSN	0277-0008
DOI	10.1002/phar.2892
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1738: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 585: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Risk of kidney injury in patients on concomitant oral vancomycin and piperacillin-tazobactam: Analysis of the pharmacovigilance database in Japan.

Mitsuboshi, Satoru / Katagiri, Hiroki

Basic & clinical pharmacology & toxicology

2021 Volume 130, Issue 1, Page(s) 208–212

MeSH term(s)	Acute Kidney Injury/chemically induced ; Administration, Oral ; Age Factors ; Aged ; Aged, 80 and over ; Databases as Topic ; Drug Therapy, Combination ; Female ; Humans ; Japan/epidemiology ; Male ; Middle Aged ; Pharmacovigilance ; Piperacillin, Tazobactam Drug Combination/administration & dosage ; Piperacillin, Tazobactam Drug Combination/adverse effects ; Risk Factors ; Sex Factors ; Vancomycin/administration & dosage ; Vancomycin/adverse effects
Chemical Substances	Piperacillin, Tazobactam Drug Combination (157044-21-8) ; Vancomycin (6Q205EH1VU)
Language	English
Publishing date	2021-11-30
Publishing country	England
Document type	Journal Article ; Observational Study
ZDB-ID	2134679-3
ISSN	1742-7843 ; 1742-7835
ISSN (online)	1742-7843
ISSN	1742-7835
DOI	10.1111/bcpt.13689
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.144: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Effect of cytochrome P450 1A2 inhibitors on rhabdomyolysis in patients on clozapine: Analysis using the US Food and Drug Administration's Adverse Event Reporting System.

Kotake, Kazumasa / Mitsuboshi, Satoru / Hosokawa, Tomonari / Kitamura, Naoya / Kawakami, Yasuhiro

Schizophrenia research

2023 Volume 262, Page(s) 102–103

MeSH term(s)	Humans ; Clozapine/adverse effects ; Rhabdomyolysis/chemically induced ; Rhabdomyolysis/drug therapy ; United States ; United States Food and Drug Administration ; Cytochrome P-450 CYP1A2 Inhibitors/pharmacology ; Cytochrome P-450 CYP1A2 Inhibitors/therapeutic use ; Antipsychotic Agents/adverse effects
Chemical Substances	Clozapine (J60AR2IKIC) ; Cytochrome P-450 CYP1A2 Inhibitors ; Antipsychotic Agents
Language	English
Publishing date	2023-11-07
Publishing country	Netherlands
Document type	Letter
ZDB-ID	639422-x
ISSN	1573-2509 ; 0920-9964
ISSN (online)	1573-2509
ISSN	0920-9964
DOI	10.1016/j.schres.2023.10.042
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2351: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 543: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluation of Preoperative Risk Factors for Sugammadex-Induced Anaphylaxis: Analysis of the Japanese Adverse Drug Event Report Database.

Kotake, Kazumasa / Mitsuboshi, Satoru / Kawakami, Yasuhiro

Journal of clinical pharmacology

2022 Volume 62, Issue 12, Page(s) 1574–1575

MeSH term(s)	Humans ; Sugammadex/adverse effects ; Anaphylaxis/chemically induced ; Japan/epidemiology ; Drug-Related Side Effects and Adverse Reactions ; Risk Factors
Chemical Substances	Sugammadex (361LPM2T56)
Language	English
Publishing date	2022-07-05
Publishing country	England
Document type	Letter
ZDB-ID	188980-1
ISSN	1552-4604 ; 0091-2700 ; 0021-9754
ISSN (online)	1552-4604
ISSN	0091-2700 ; 0021-9754
DOI	10.1002/jcph.2114
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uf I Zs.176: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito